Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections

N. A. Halsey, P. J. Chesney, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, M. I. Marks, D. L. Murray, J. C. Overall, L. K. Pickering, R. J. Whitley, R. Yogev, G. Peter, R. L. Berkelman, M. C. Hardgree, R. F. Jacobs, N. E. MacDonald, W. A. Orenstein, N. R. Rabinovich

Research output: Contribution to journalReview articlepeer-review

165 Scopus citations


The purpose of this statement is to inform practitioners about new information concerning lack of demonstrated clinical effectiveness of ribavirin in the treatment of infants with respiratory syncytial virus (RSV) disease. The intent of the new recommendation is to allow practitioners to decide whether ribavirin therapy is appropriate or not by taking into account the particular clinical situation and their own preferences. More definitive answers to the questions of ribavirin efficacy and effectiveness will require multi-institutional, prospective, randomized clinical trials. Recommendations may be modified as new information becomes available.

Original languageEnglish (US)
Pages (from-to)137-140
Number of pages4
Issue number1
StatePublished - Jan 1996
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections'. Together they form a unique fingerprint.

Cite this